Jonathan Alspaugh - 16 Aug 2021 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Chief Financial Officer
Signature
/s/ Steven Weber, by power of attorney
Issuer symbol
SYRE
Transactions as of
16 Aug 2021
Net transactions value
+$262,660
Form type
4
Filing time
18 Aug 2021, 17:21:54 UTC
Previous filing
08 Jul 2021
Next filing
13 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGLE Common Stock Purchase $62,275 +9,780 $6.37 9,780 16 Aug 2021 Direct F1
transaction AGLE Common Stock Purchase $151,985 +23,392 +239% $6.50 33,172 17 Aug 2021 Direct F2
transaction AGLE Common Stock Purchase $48,400 +7,200 +22% $6.72 40,372 18 Aug 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.13 to $6.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
F2 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.6 per share, inclusive.
F3 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.69 to $6.77 per share, inclusive.